Premium
The influence of acetylator phenotype on the effects of treating depression with phenelzine
Author(s) -
Price Evans David A.,
Davison K.,
Pratt R. T. C.
Publication year - 1965
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt196564430
Subject(s) - phenelzine , isoniazid , hydralazine , pharmacology , phenotype , polymorphism (computer science) , medicine , chemistry , genetics , genotype , enzyme , biology , monoamine oxidase , biochemistry , gene , pathology , tuberculosis , blood pressure
There is a clear polymorphism for the acetylation of isoniazid, sulfamethazine, and hydralazine, so that human beings are clearly divisible into either slow or rapid acetylators. From its molecular configuration, it is likely that phenelZine is a substrate for the enzyme liver acetyl transferase which is responsible for the polymorphism. In the present investigation the responses of 47 depressive patients treated with phenelZine were observed. These responses were later correlated with acetylator phenotypes. Two results were obtained. First, there were no significant differences in the improvement of rating scores between the two phenotypes. Second, severe adverse effects were more common among slow acetylators treated with phenelzine than among rapid acetylators on the same treatment schedule.